Cancer ‘master switch’ study expands to lung cancer

Non-small cell lung cancer

iOnctura has expanded its clinical trial programme for roginolisib to include non-small cell lung cancer (NSCLC).

Via clinical collaboration agreements with the ETOP IBCSG Partners Foundation and GSK, roginolisib will be evaluated in a Phase II study in combination with dostarlimab in patients with NSCLC resistant to first-line checkpoint inhibitor therapy.

Roginolisib is an allosteric modulator of PI3Kδ, referred to as a ‘master switch’ of cancer. It has demonstrated an unprecedented clinical profile in solid and liquid cancers, with 44 patients treated to date.

Inhibition of PI3Kδ unleashes a multi-pronged anti-tumour and immune response to combat the tumour.

Emerging clinical and translational biomarker data supports the hypothesis that combining roginolisib with a programmed death receptor-1 (PD-1) targeting agent, with or without docetaxel, may prevent or reverse drug resistance in NSCLC and may show synergistic anti-tumour immune activity without significant addition of toxicity.

Dostarlimab is a PD-1-blocking antibody approved for certain patients with endometrial cancer, which has also demonstrated clinical activity in combination with chemotherapy in NSCLC.

Solange Peters, Professor and Chair of Medical Oncology & Thoracic Malignancies Programme in the Department of Oncology at the University Hospital of Lausanne in Lausanne, Switzerland, and primary coordinating investigator of the study, commented: “On behalf of the ETOP IBCSG Partners Foundation, we are intrigued by the benefit/risk profile of roginolisib. In patients who no longer respond to current therapies, we wish to investigate whether roginolisib in combination with dostarlimab provides a novel treatment option. ETOP IBCSG Partners Foundation is committed to investigate novel treatment options to help our patients.”

In June 2024, iOnctura closed an €80 million Series B financing to support the continued development of its precision oral small molecules targeting cancers.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free